Funding for this research was provided by:
Association pour la Recherche Thérapeutique Anti-Cancéreuse
fondation de francefondation ligue contre le cancer
Agence Nationale de la Recherche (ANR-11-LABX0021)
Received: 1 April 2021
Accepted: 13 December 2021
First Online: 31 January 2022
: F.G. received honoraria for oral communication from Lilly, Sanofi, BMS, Astra Zeneca and Amgen; received funding for clinical trials by Astra Zeneca; received a travel grant from Roche France, Amgen and Servier; and is an advisory board member for Merck Serano, Amgen, Roche France and Sanofi. All other authors have no competing interests.